MicroRNA-9 inhibits proliferation and Progression In retinoblastoma Cells By targeting PTEN
Overview
Authors
Affiliations
Background: Retinoblastoma (RB) is the most prevalent primary intraocular malignancy, which commonly occurs during infant and childhood.
Objective: Our study aimed to investigate whether microRNA-9 (miR-9) could regulate RB cells and its mechanism.
Methods: qRT-PCR analysis was used to detect the expression of miR-9. In addition, to detect the migration of RB cells, wound healing assay was conducted. Xenograft tumor models in nude mice were also established, in order to assess the effects of miR-9 on tumor growth. qRT-PCR, luciferase reporter assay and western blot analysis were used to detect the target of miR-9.
Results: Initially, the expression level of miR-9 was significantly decreased in the RB tissues and blood samples from patients with RB. qRT-PCR, luciferase reporter assay and western blot analysis were used to confirm that PTEN was the target genes of miR-9 and it was negatively regulated by miR-9. When the expression of miR-9 was up-regulated, the cell viability, proliferation, migration and tumor formation were significantly suppressed. Furthermore, the expression level of PTEN was decreased after transfection of miR-9 mimic. Taken together, these results indicated that miR-9 might suppress the cell viability, proliferation, migration and tumor formation in RB by inhibiting PTEN.
Conclusion: The in vitro and in vivo experiments demonstrated that miR-9 acts as a tumor suppressor function in RB cells and might serve as novel therapeutic targets for the treatment of RB.
MicroRNAs' Significance in Retinoblastoma Diagnosis and Treatment: The Little Heroes.
Zamani Sani M, Mirzaei M, Mota A, Mohammadian J, Beilankouhi E, Rahmati M Biochem Genet. 2025; .
PMID: 39862293 DOI: 10.1007/s10528-024-10976-2.
Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression.
Ahangar Davoodi N, Najafi S, Ghale-Noie Z, Piranviseh A, Mollazadeh S, Ahmadi Asouri S Front Cell Dev Biol. 2023; 10:1065837.
PMID: 36619866 PMC: 9816416. DOI: 10.3389/fcell.2022.1065837.
Pal R, Kowalik M, Serra M, Migliore C, Giordano S, Columbano A Cell Prolif. 2022; 55(4):e13199.
PMID: 35174557 PMC: 9055901. DOI: 10.1111/cpr.13199.